ML218

SIGMA/SML0385 - ≥98% (HPLC)

Synonym: 3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]benzamide; CID 45115620; VU0413807; VU0424199-1

CAS Number: 1346233-68-8
Empirical Formula (Hill Notation): C₁₉H₂₆Cl₂N₂O
Molecular Weight: 369.33
Linear Formula: C₁₉H₂₆Cl₂N₂O
Product Type: Chemical

assay	≥98% (HPLC)
color	white to beige
form	powder
InChI	1S/C19H26Cl2N2O/c1-19(2,3)4-5-23-10-16-15(17(16)11-23)9-22-18(24)12-6-13(20)8-14(21)7-12/h6-8,15-17H,4-5,9-11H2,1-3H3,(H,22,24)/t15-,16-,17+
InChI key	GSJIGYLGKSBYBC-OSYLJGHBSA-N
Quality Level	100
SMILES string	CC(C)(C)CCN1C[C@H]2C(CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1
solubility	DMSO: 10 mg/mL (clear solution)
storage temp.	2-8°C

Application:	ML218 has been used as a: • T-type channel blocker to test its effect on the nociceptive behavior associated with homocysteinemia rats • T-type voltage-sensitive calcium channel (VSCC) inhibitor in osteoblasts • T-type calcium channel blocker to test its effect on the viability of neural progenitor cells
Biochem/physiol Actions:	ML218 (CID 45115620) is a potent and selective T-Type (Cav3.1, Cav3.2, Cav3.3) calcium channel inhibitor (Cav3.2, IC50 = 150 nM in Ca2+ flux; Cav3.2 IC50 = 310 nM and Cav3.3 IC50 = 270 nM with good Drug metabolism/Pharmacokinetics. In a panel of 68 GPCRs, ion channels and transporters, ML218 was found to bind significantly only two other targets (sodium channel site 2 and sigma 1) and had no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. It showed robust inhibition of calcium current in STN neurons and was orally active in a rodent model of Parkinson’s Disease.
Features and Benefits:	This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here .
Packaging:	5, 25 mg in glass bottle

RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable